Navigation Links
Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
Date:9/2/2007

ia and, perhaps, other neuropsychiatric disorders," said Steven Paul, M.D., Lilly's executive vice president of science and technology. "Additional and longer-term studies are needed to confirm and extend these exciting initial findings. However, these data suggest that LY2140023 may provide a new alternative for the treatment of this often devastating condition."

Study Design

The trial was a proof of concept study designed to determine LY2140023 superiority versus placebo. Olanzapine was used as an active control. 196 patients with schizophrenia were randomly assigned to LY2140023 (40 mg twice daily), olanzapine (15 mg daily) or placebo. All participants were hospitalized to ensure patient safety, tapered off from any pre-trial antipsychotic medications (no therapeutically stable patients were included in the trial), and treated in a double-blind manner for four weeks. In all, 118 patients completed four weeks of the planned study treatment.

Results

Treatment with LY2140023 or olanzapine resulted in statistically significant improvement in PANSS (Positive and Negative Syndrome Scale) total score (primary outcome) compared to placebo (-20.8, P < 0.001; -26.7, P < 0.001; respectively), After four weeks of treatment, the study showed that both the LY2140023 group (32.0%, P < 0.001) and the olanzapine group (41.2%, P < 0.001) demonstrated significantly greater response rates compared to the placebo group (3.2%). Response was measured primarily by the PANSS, the most common scale used for measuring symptoms of patients with schizophrenia. A patient showing a 25% or more decrease in PANSS total score was defined as a responder. Additionally, a mean 0.51-kg weight reduction from baseline was observed in the LY2140023 group. A moderate but statistically significant weight gain was observed in the olanzapine group (0.74 kg, P = 0.017) relative to the placebo group.

Results showed that the placebo arm experienced the highest rate of study discon
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Effective And Economical Agent For Anthrax
6. New target for antidiabetic agents identified
7. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
8. A potent causative agent of dental flourosis: Fluoride
9. Another causative agent of adult onset asthma : Atopy
10. Revelation Of Cancer Agent Could Help In Developing Effective Cancer Drugs
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... made it clear that a mother,s eating habits prior ... profound impact on her offspring and their propensity for ... the mechanisms behind this phenomenon were unclear. According to ... The FASEB Journal F , scientists using ... mother,s diet and an offspring,s risk of future obesity. ...
(Date:9/2/2014)... believe that marijuana is not addictive, but a new ... able to obtain and consume cannabis legally for medical ... likely to perceive it as addictive or harmful," study ... Center for Addiction Medicine, said in a hospital news ... have significant consequences, and we know that among adolescents ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... Healthcare professionals will be able to access ... available at the point of care following an agreement ... Comprehensive Cancer Network® (NCCN®). Information from NCCN will ... the content available from the clinical reference tool ... of 25 of the world's leading cancer centers devoted ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
Breaking Medicine News(10 mins):Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2
... Results of VICTOR-E1 Phase II Study Presented at 15th ... Retroviruses and Opportunistic Infections (CROI), ... ) today reported that final results of a Phase ... potent,and sustained viral suppression through 48 weeks of therapy ...
... one can put on the brain cancer glioblastoma is that ... It is nearly always fatal, it tends to strike people ... options have changed little over decades. Its no wonder then ... this poorly understood type of cancer. , One approach ...
... New Deloitte Center for Health Solutions study outlines ... illnesses, coordinate care, WASHINGTON, Feb. 6 ... their patients, chronic diseases,and be compensated accordingly for ... study from the Deloitte Center for Health Solutions,( ...
... Revenues, Gross Margins and Net Income in Company History, ... DSCM ), a leading online provider of health, beauty, ... the fourth,quarter and fiscal year ended December 30, 2007. ... net income of $156,000, or $0.00,per share. The company ...
... - Q4 2007 ... - Q4 2007 book to bill ratio of 1.44, - ... ... PPD, Inc. (Nasdaq:,PPDI) today reported its financial and operating results for the fourth,quarter and full year ...
... ARLINGTON, Va., Feb. 6 The HealthCentral,Network, Inc. ... an accomplished dermatologist, cosmetic surgeon and author, is,joining ... expert. Sundaram is the author of Face Value: ... Finding It [Rodale], which was honored by,the National ...
Cached Medicine News:Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 2Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 3Health News:Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients 4Health News:Gene plays 'Jekyll and Hyde' in brain cancer 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 3Health News:The Medical Home: Building a Framework of Higher Quality, Reduced Cost and Patient-Centric Care 2Health News:The Medical Home: Building a Framework of Higher Quality, Reduced Cost and Patient-Centric Care 3Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 2Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 3Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 4Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 5Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 6Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 7Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 8Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 9Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 10Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 11Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 12Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 13Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 14Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 15Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 16Health News:drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007 17Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:PPD Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 2Health News:Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com 3
(Date:9/2/2014)...  PANTHERx Specialty Pharmacy announced today that it ... a Washington, DC -based health ... the health care industry. Logo - ... accreditation process demonstrates a commitment to quality services ... processes through benchmarking organizations against nationally recognized standards. ...
(Date:9/2/2014)... Actavis plc (NYSE: ACT ) ... (FDA) has accepted for filing Actavis, New Drug Application ... of diarrhea and abdominal pain in men and women ... for eluxadoline has been granted priority review status by ... "The NDA filing of eluxadoline marks an ...
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation ... previously announced agreement to purchase the Interventional business ... of Boston Scientific to offer physicians and healthcare ... treat challenging vascular conditions. The addition ... innovative technologies supports the Boston Scientific strategy to ...
Breaking Medicine Technology:PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
... DTX Series Multimode Detectors provide unmatched ... of application and automation needs. Capable ... measurements on the same instrument, the ... instruments or can be integrated seamlessly ...
... PCR, cDNA and Oligonucleotides The Tecan ... a variety applications that are quantified by Fluorescence, ... handle assays in Microplate formats from 6 ... Cuvettes Independent whether you have to ...
... Designed for Ultra High Throughput Screening ... assay detection performance. Allows for smooth ... assay development by sharing all the ... HT, fluorescence intensity, fluorescence polarization, time-resolved ...
... system used to detect and quantitate contaminants, ... cell protein, bovine contaminants (e.g., BSA, IgG, ... any unique protein that can be bound ... and plasmid copy number. The system reduces ...
Medicine Products: